1a. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis and classification of diabetes mellitus. 2003 Diabetes Care 26:3160-3167

2. Atkinson, M.A., N.K. Maclaren, and R. Luchetta. 1990. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39, no. 8:p933.

3. Shah, S.C., J.I. Malone, and N.E. Simpson. 1989. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320, no. 9:p550.

4. Kobayashi T, T.S. 2001. Early insulin intervention to preserve beta - cells. Novo-Nordisk Diabetes Update:51.

5. Kobayashi, T., K. Nakanishi, T. Murase, and K. Kosaka. 1996. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45, no. 5:p622.

6. Hiramatsu, S., A. Hoog, C. Moller, and V. Grill. 2000. Treatment with diazoxide causes prolonged improvement of beta-cell function in rat islets transplanted to a diabetic environment. Metabolism 49, no. 5:p657.

7. Bjork, E., C. Berne, and F.A. Karlsson. 1998. Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. Diabetes Care 21, no. 3:p427.

8. Bjork, E., C. Berne, O. Kampe, L. Wibell, P. Oskarsson, and F.A. Karlsson. 1996. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45, no. 10:p1427.

9. Vlahos, W.D., T.A. Seemayer, and J.F. Yale. 1991. Diabetes prevention in BB rats by inhibition of endogenous insulin secretion. Metabolism 40, no. 8:p825.

10. Sako, Y., and V.E. Grill. 1992. Diazoxide infusion at excess but not at basal hyperglycemia enhances beta-cell sensitivity to glucose in vitro in neonatally streptozotocin-diabetic rats. Metabolism 41, no. 7:p738.

11. Rasmussen, S.B., T.S. Sorensen, J.B. Hansen, T. Mandrup-Poulsen, L. Hornum, and H. Markholst. 2000. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Horm Metab Res 32, no. 7:p294.

12. Bowman, M.A., L. Campbell, B.L. Darrow, T.M. Ellis, A. Suresh, and M.A. Atkinson. 1996. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45, no. 2:p205.

13. Schnell, O., B. Eisfelder, E. Standl, and A.G. Ziegler. 1997. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 46, no. 10:p1607.

14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. 1993 N Engl J Med 329:977.

15. Reichard, P., B.Y. Nilsson, and U. Rosenqvist. 1993. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329, no. 5:p304.

16. Wang, P.H., J. Lau, and T.C. Chalmers. 1993. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341, no. 8856:p1306.

17. Neesha Ramchandani, Svetlana Ten, Abigail I. Kamishlian, Henry Anhalt,, Anjli Kukreja, and Noel K. Maclaren. 2003. Insulin pump therapy from diagnosis of type1 diabetes - results from the first 6 months. Diabetes, ADA, 63 rd Scientific Sessions 52, Supplement 1:Abstract 439.

18. Boland E, W.S., Ahern, JA, Steffen A, Tamborlane W. 2003. Randomized, Prospective Trial of CSII vs MDI with Glargine in Children: A preliminary Report. Diabetes 52, no. Supplement 1:Abstract 192.

19. Cohen D, W.N., Hadassa B, Avinoam G, Gila F, Moshe P. 2003. Continuous Subcutaneous Insulin Infusion (CSII) Versus Multiple Daily Injections in Adolescents (MDI) with Type 1 Diabetes: A Randomized Open Crossover Trial. The Endocrine Society's 85th Annual Meeting:P1-612.

20. Tsui, E., A. Barnie, S. Ross, R. Parkes, and B. Zinman. 2001. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 24, no. 10:p1722.

21. Reeves, M.L., D.E. Seigler, E.A. Ryan, and J.S. Skyler. 1982. Glycemic control in insulin-dependent diabetes mellitus. Comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion. Am J Med 72, no. 4:p673.

22. Shapiro, E.T., H. Tillil, K.S. Polonsky, V.S. Fang, A.H. Rubenstein, and E. Van Cauter. 1988. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab 67, no. 2:p307.

23. Galloway, J.A., and R.E. Chance. 1994. Improving insulin therapy: achievements and challenges. Horm Metab Res 26, no. 12:p591.

24. Bode, B.W., W.V. Tamborlane, and P.C. Davidson. 2002. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 111, no. 5:p69.

25. Bode, B.W., H.T. Sabbah, T.M. Gross, L.P. Fredrickson, and P.C. Davidson. 2002. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 18, no. Suppl 1:S14.

26. Vora, J.P., A. Burch, J.R. Peters, and D.R. Owens. 1992. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 15, no. 11:p1484.

27. Davidson P, H.H., Steed RD, Bode BW. 2003. Deductive framework to aid in understanding CSII PArameters: Carbohydrate - To-Insulin ration (CIR) and Correction Factor (CF). Diabetes 52, Supplement (1):443.

28. King AB, A.D., Haler S, Gross TM, Fredrickson LP. 2002. Continuous glucose monitoring provides a novel method for evaluating rule - based estimates of insulin sensitivity. Diabetes 51, Supplement (1):422.

29. Dickey, R.A., and S. Feld. 2002. A new paradigm for control of diabetes. Endocr Pract 8, no. 1:p65.

30. Davidson, J. 2003. Should postprandial glucose be measured and treated to a particular target? Diabetes Care 26, no. 6:p1919.

31. Consensus Development Conference 2002. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocrine Practice 8, Suppl 1:5.

32. Heinemann, L., R. Linkeschova, K. Rave, B. Hompesch, M. Sedlak, and T. Heise. 2000. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23, no. 5:p644.

33. Rosenstock, J., G. Park, and J. Zimmerman. 2000. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23, no. 8:p1137.

34. Ratner, R.E., I.B. Hirsch, J.L. Neifing, S.K. Garg, T.E. Mecca, and C.A. Wilson. 2000. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23, no. 5:p639.

35. Lepore, M., S. Pampanelli, C. Fanelli, F. Porcellati, L. Bartocci, A. Di Vincenzo, C. Cordoni, E. Costa, P. Brunetti, and G.B. Bolli. 2000. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49, no. 12:p2142.

36. Zinman, B., H. Tildesley, J.L. Chiasson, E. Tsui, and T. Strack. 1997. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46, no. 3:p440.

37. Brunelle, B.L., J. Llewelyn, J.H. Anderson, E.A. Gale, and V.A. Koivisto. 1998. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21, no. 10:p1726.

38. Dunn, F.L., D.M. Nathan, M. Scavini, J.L. Selam, and T.G. Wingrove. 1997. Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care 20, no. 1:p59.

39. Saudek, C.D., W.C. Duckworth, A. Giobbie-Hurder, W.G. Henderson, R.R. Henry, D.E. Kelley, S.V. Edelman, F.J. Zieve, R.A. Adler, J.W. Anderson, R.J. Anderson, B.P. Hamilton, T.W. Donner, M.S. Kirkman, and N.A. Morgan. 1996. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. Jama 276, no. 16:p1322.

40. Guinn, T.S., G.J. Bailey, and R.S. Mecklenburg. 1988. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care 11, no. 1:p46.

41. Woodworth, J.R., D.C. Howey, R.R. Bowsher, R.L. Brunelle, H.M. Rowe, J. Compton, and B. Cerimele. 1994. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 17, no. 5:p366.

42. Pietropaolo M, G.N., Trucco M. 2002, p 610. Immunologically Mediated Endocrine Diseases, ed. N.K.M. Joan T. Harmon, Ronald G. Gill. Lippincott Williams & Wilkins. p. 610 pp.

43. Baekkeskov, S., H.J. Aanstoot, S. Christgau, A. Reetz, M. Solimena, M. Cascalho, F. Folli, H. Richter-Olesen, P. De Camilli, and P.D. Camilli. 1990. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published erratum appears in Nature 1990 Oct 25; 347(6295):782]. Nature 347, no. 6289:p151.

44. Rabin, D.U., S.M. Pleasic, J.A. Shapiro, H. Yoo-Warren, J. Oles, J.M. Hicks, D.E. Goldstein, and P.M. Rae. 1994. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152, no. 6:p3183.

45. Lan, M.S., C. Wasserfall, N.K. Maclaren, and A.L. Notkins. 1996. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 93, no. 13:6367.

46. Husebye, E.S., G. Gebre-Medhin, T. Tuomi, J. Perheentupa, M. Landin-Olsson, J. Gustafsson, F. Rorsman, and O. Kampe. 1997. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 82, no. 1:p147.

47. Betterle, C., M. Volpato, B. Pedini, S. Chen, B.R. Smith, and J. Furmaniak. 1999. Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays. J Clin Endocrinol Metab 84, no. 2:p618.

48. Kukreja, A., and N.K. Maclaren. 1999. Autoimmunity and diabetes. J Clin Endocrinol Metab 84, no. 12:p4371.

49. Kong, M.F., and W. Jeffcoate. 1994. Eighty-six cases of Addison's disease. Clin Endocrinol (Oxf 41, no. 6:p757.

50. Winqvist, O., F.A. Karlsson, and O. Kampe. 1992. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339, no. 8809:p1559.

51. Bednarek, J., J. Furmaniak, N. Wedlock, Y. Kiso, A. Baumann-Antczak, S. Fowler, H. Krishnan, J.A. Craft, and B. Rees Smith. 1992. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett 309, no. 1:p51.

52. Kim, T.J., J.N. Anasti, M.R. Flack, L.M. Kimzey, R.A. Defensor, and L.M. Nelson. 1997. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 89, no. 5 Pt 1:p777.

53. Krohn, K., R. Uibo, E. Aavik, P. Peterson, and K. Savilahti. 1992. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet 339, no. 8796:p770.

54. Arif, S., S. Vallian, F. Farzaneh, M.M. Zanone, S.L. James, M. Pietropaolo, S. Hettiarachchi, D. Vergani, G.S. Conway, and M. Peakman. 1996. Identification of 3 beta-hydroxysteroid dehydrogenase as a novel target of steroid cell autoantibodies: association of autoantibodies with endocrine autoimmune disease. J Clin Endocrinol Metab 81, no. 12:p4439.

55. Menon, P.S., B. Vaidyanathan, and M. Kaur. 2001. Autoimmune thyroid disease in Indian children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 14, no. 3:p279.

56. Andersson, D.K., K. Svardsudd, and G. Tibblin. 1991. Prevalence and incidence of diabetes in a Swedish community 1972-1987. Diabet Med 8, no. 5:p428.

57. Czarnocka, B., J. Ruf, M. Ferrand, P. Carayon, and S. Lissitzky. 1985. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Lett 190, no. 1:p147.

58. Makinen, T., G. Wagar, L. Apter, E. von Willebrand, and F. Pekonen. 1978. Evidence that the TSH receptor acts as a mitogenic antigen in Graves' disease. Nature 275, no. 5678:p314.

59. Li, Y., Y.H. Song, N. Rais, E. Connor, D. Schatz, A. Muir, and N. Maclaren. 1996. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 97, no. 4:p910.

60. Song, Y.H., E.L. Connor, A. Muir, J.X. She, B. Zorovich, D. Derovanesian, and N. Maclaren. 1994. Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison's disease. J Clin Endocrinol Metab 78, no. 5:1108.

61. Hedstrand, H., O. Ekwall, M.J. Olsson, E. Landgren, E.H. Kemp, A.P. Weetman, J. Perheentupa, E. Husebye, J. Gustafsson, C. Betterle, O. Kampe, and F. Rorsman. 2001. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem 276, no. 38:p35390.

62. Hedstrand, H., O. Ekwall, J. Haavik, E. Landgren, C. Betterle, J. Perheentupa, J. Gustafsson, E. Husebye, F. Rorsman, and O. Kampe. 2000. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochem Biophys Res Commun 267, no. 1:p456.

63. De Block, C.E., I.H. De Leeuw, J.J. Vertommen, R.P. Rooman, M.V. Du Caju, C.M. Van Campenhout, J.J. Weyler, F. Winnock, J. Van Autreve, and F.K. Gorus. 2001. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin Exp Immunol 126, no. 2:p236.

64. Karlsson, F.A., P. Burman, L. Loof, and S. Mardh. 1988. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+,K+-adenosine triphosphatase of the stomach. J Clin Invest 81, no. 2:475.

65. Toh, B.H., P.A. Gleeson, R.J. Simpson, R.L. Moritz, J.M. Callaghan, I. Goldkorn, C.M. Jones, T.M. Martinelli, F.T. Mu, D.C. Humphris, and et al. 1990. The 60- to 90-kDa parietal cell autoantigen associated with autoimmune gastritis is a beta subunit of the gastric H+/K(+)-ATPase (proton pump). Proc Natl Acad Sci U S A 87, no. 16:p6418.

66. Gregorio, G.V., B. Portmann, F. Reid, P.T. Donaldson, D.G. Doherty, M. McCartney, A.P. Mowat, D. Vergani, and G. Mieli-Vergani. 1997. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25, no. 3:p541.

67. Manns, M. 1987. [Heterogeneity of autoimmune chronic active hepatitis. Differentiation of SLA-autoantibody positive chronic active hepatitis]. Fortschr Med 105, no. 19:p376.

68. M.G. Clemente, P. Obermayer-Straub, A. Meloni, C.P. Strassburg, V. Arangino, R.H. Tukey, S. De Virgiliis, and M.P. Manns. 1997. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 82, no. 5:p1353.

69. Strassburg, C.P., B. Alex, F. Zindy, G. Gerken, B. Luttig, K.H. Meyer zum Buschenfelde, C. Brechot, and M.P. Manns. 1996. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 25, no. 6:p859.

70. Strassburg, C.P., P. Obermayer-Straub, B. Alex, M. Durazzo, M. Rizzetto, R.H. Tukey, and M.P. Manns. 1996. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111, no. 6:p1576.

71. Dieterich, W., T. Ehnis, M. Bauer, P. Donner, U. Volta, E.O. Riecken, and D. Schuppan. 1997. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3, no. 7:797.

72. Picarelli, A., L. Maiuri, A. Frate, M. Greco, S. Auricchio, and M. Londei. 1996. Production of antiendomysial antibodies after in-vitro gliadin challenge of small intestine biopsy samples from patients with coeliac disease [see comments]. Lancet 348, no. 9034:p1065.

73. Maki, M. 1996. Coeliac disease and autoimmunity due to unmasking of cryptic epitopes? [comment]. Lancet 348, no. 9034:p1046.

74. Ekwall, O., H. Hedstrand, L. Grimelius, J. Haavik, J. Perheentupa, J. Gustafsson, E. Husebye, O. Kampe, and F. Rorsman. 1998. Identification of tryptophan hydroxylase as an intestinal autoantigen [see comments]. Lancet 352, no. 9124:p279.

75. Ekwall, O., H. Hedstrand, J. Haavik, J. Perheentupa, C. Betterle, J. Gustafsson, E. Husebye, F. Rorsman, and O. Kampe. 2000. Pteridin-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 85, no. 8:p2944.

76. Wertman, E., N. Zilber, and O. Abramsky. 1992. An association between multiple sclerosis and type I diabetes mellitus. J Neurol 239, no. 1:p43.

77. Hermitte, L., N. Martin-Moutot, J. Boucraut, R. Barone, C. Atlan-Gepner, M. Seagar, J. Pouget, J.P. Kleisbauer, F. Couraud, and B. Vialettes. 2000. Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome. J Clin Immunol 20, no. 4:p287.

78. American Diabetes Association: 2001. Clinical Practice Recommendations. Diabetes Care 24:562-563.

78a. Ryan EA, Imes S, Wallace C. 2004. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27(5):1028-32.

79. Yki-Jarvinen, H. 2000. Comparison of insulin regimens for patients with type 2 diabetes [Record Supplied By Aries Systems]. Curr Opin Endocrin Diabetes 7, no. 4:p175.

80. Rosenstock, J. 2001. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 4, no. 2:p50.

81. Garvey, W.T., J.M. Olefsky, J. Griffin, R.F. Hamman, and O.G. Kolterman. 1985. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34, no. 3:p222.

82. Jennings, A.M., K.S. Lewis, S. Murdoch, J.F. Talbot, C. Bradley, and J.D. Ward. 1991. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 14, no. 8:p738.

83. UK Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854.

84. Nathan, D.M. 2002. Clinical review 146: The impact of clinical trials on the treatment of diabetes mellitus. J Clin Endocrinol Metab 87, no. 5:p1929.

85. Shichiri, M., H. Kishikawa, Y. Ohkubo, and N. Wake. 2000. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23, no. Suppl 2:B21.

86. Scarlett, J.A., R.S. Gray, J. Griffin, J.M. Olefsky, and O.G. Kolterman. 1982. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5, no. 4:p353.

87. Andrews, W.J., B. Vasquez, M. Nagulesparan, I. Klimes, J. Foley, R. Unger, and G.M. Reaven. 1984. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33, no. 7:p634.

88. Leahy, J.L., L.M. Bumbalo, and C. Chen. 1994. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 43, no. 2:p173.

89. Buchanan, T.A., A.H. Xiang, R.K. Peters, S.L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H.N. Hodis, and S.P. Azen. 2002. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51, no. 9:p2796.

90. Kay, J.P., R. Alemzadeh, G. Langley, L. D'Angelo, P. Smith, and S. Holshouser. 2001. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50, no. 12:p1457.

91. Freemark, M., and D. Bursey. 2001. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107, no. 4:pE55.

92. Jones, K.L., S. Arslanian, V.A. Peterokova, J.S. Park, and M.J. Tomlinson. 2002. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 25, no. 1:p89.

93. Knowler, W.C., E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, and D.M. Nathan. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, no. 6:p393.

94. Morrison, J.A., E.M. Cottingham, and B.A. Barton. 2002. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 159, no. 4:p655.

95. Nestler, J.E., and D.J. Jakubowicz. 1996. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335, no. 9:p617.

96. Sarlis, N.J., S.J. Weil, and L.M. Nelson. 1999. Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. J Clin Endocrinol Metab 84, no. 5:p1510.

97. Jakubowicz, D.J., M.J. Iuorno, S. Jakubowicz, K.A. Roberts, and J.E. Nestler. 2002. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87, no. 2:p524.

98. Kersten, S. 2002. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 440, no. 2-3:p223.

99. Aljada, A., H. Ghanim, J. Friedman, R. Garg, P. Mohanty, and P. Dandona. 2001. Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects. J Clin Endocrinol Metab 86, no. 7:p3130.

100. Hasstedt, S.J., Q.F. Ren, K. Teng, and S.C. Elbein. 2001. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 86, no. 2:p536.

101. Ghanim, H., R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona. 2001. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86, no. 3:p1306.

102. Marx, N., T. Bourcier, G.K. Sukhova, P. Libby, and J. Plutzky. 1999. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19, no. 3:p546.

103. Dunaif, A., D. Scott, D. Finegood, B. Quintana, and R. Whitcomb. 1996. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81, no. 9:p3299.

104. Nakamura, T., T. Funahashi, S. Yamashita, M. Nishida, Y. Nishida, M. Takahashi, K. Hotta, H. Kuriyama, S. Kihara, N. Ohuchi, T. Nishimura, B.I. Kishino, K. Ishikawa, T. Kawamoto, K. Tokunaga, C. Nakagawa, I. Mineo, F. Watanabe, S. Tarui, and Y. Matsuzawa. 2001. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. Diabetes Res Clin Pract 54, no. 3:p181.

105. Chiasson, J.L., R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso. 2002. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, no. 9323:p2072.

106. Hollander, P.A., S.C. Elbein, I.B. Hirsch, D. Kelley, J. McGill, T. Taylor, S.R. Weiss, S.E. Crockett, R.A. Kaplan, J. Comstock, C.P. Lucas, P.A. Lodewick, W. Canovatchel, J. Chung, and J. Hauptman. 1998. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21, no. 8:p1288.

107. Bressler, R., and D.G. Johnson. 1997. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 157, no. 8:p836.

108. Fuhlendorff, J., P. Rorsman, H. Kofod, C.L. Brand, B. Rolin, P. MacKay, R. Shymko, and R.D. Carr. 1998. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47, no. 3:p345.

109. Hoffmann, J., and M. Spengler. 1997. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 103, no. 6:p483.

110. Chiasson, J.L., and L. Naditch. 2001. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 24, no. 6:p989.

111. Chiasson, J.L., R.G. Josse, J.A. Hunt, C. Palmason, N.W. Rodger, S.A. Ross, E.A. Ryan, M.H. Tan, and T.M. Wolever. 1994. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121, no. 12:p928.

112. Fujimoto, Y., M. Ohhira, N. Miyokawa, S. Kitamori, and Y. Kohgo. 1998. Acarbose-induced hepatic injury. Lancet 351, no. 9099:p340.

113. Davidson, M.H., J. Hauptman, M. Di Girolamo, J.P. Foreyt, C.H. Halsted, D. Heber, D.C. Heimburger, C.P. Lucas, D.C. Robbins, J. Chung, and S.B. Heymsfield. 1999. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Jama 281, no. 3:p235.

114. Weber, M.A. 2002. Clinical implications of aldosterone blockade. Am Heart J 144, no. 5 Suppl:pS12.

115. Yusuf, S., H. Gerstein, B. Hoogwerf, J. Pogue, J. Bosch, B.H. Wolffenbuttel, and B. Zinman. 2001. Ramipril and the development of diabetes. Jama 286, no. 15:p1882.

116. Yusuf, S., P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342, no. 3:p145.

117. Rocha, R., C.T. Stier, I. Kifor, M.R. Ochoa-Maya, H.G. Rennke, G.H. Williams, and G.K. Adler. 2000. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141, no. 10:p3871.

118. Brilla, C.G., L.S. Matsubara, and K.T. Weber. 1993. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71, no. 3:p12A.

119. Brilla, C.G., G.P. Reams, B. Maisch, and K.T. Weber. 1993. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 14, no. Suppl J:57.

120. Stamler, J., O. Vaccaro, J.D. Neaton, and D. Wentworth. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, no. 2:p434.

121. Bakris, G.L., M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh, and J. Sowers. 2000. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36, no. 3:p646.

122. American Diabetes Association. 2001. Standards of medical care for patients with diabetes mellitus. Diabetes Care 24, no. Suppl 1:S 33.

123. Lewis, E.J., L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, and I. Raz. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345, no. 12:p851.

124. Brenner, B.M., M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, and S. Shahinfar. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, no. 12:p861.

125. Hostetter, T.H. 2003. Prevention of the development and progression of renal disease [In Process Citation]. J Am Soc Nephrol 14, no. Suppl 2:S144.

126. Yusuf, S. 2002. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89, no. 2A:p18A.

127. Hayashi, K., H. Kumagai, and T. Saruta. 2003. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment [In Process Citation]. Am J Hypertens 16, no. 2:p116.

128. Sato, A., K. Hayashi, M. Naruse, and T. Saruta. 2003. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, no. 1:p64.

129. American Diabetes Association. 2003. Management of Dyslipidemia in Children and Adolescents With Diabetes. Diabetes Care 26:2194-2197.

130. Marx, N., G.K. Sukhova, T. Collins, P. Libby, and J. Plutzky. 1999. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, no. 24:p3125.

131. Jeng, J.R., C.Y. Jeng, W.H. Sheu, M.M. Lee, S.H. Huang, and S.M. Shieh. 1997. Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. Am Heart J 134, no. 3:p565.

132. Jonkers, I.J., M.F. Mohrschladt, R.G. Westendorp, A. van der Laarse, and A.H. Smelt. 2002. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 112, no. 4:p275.

133. Palinski, W., and S. Tsimikas. 2002. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis [In Process Citation]. J Am Soc Nephrol 13, no. 6:p1673.

134. Freeman, D.J., J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe, I. Ford, C. Isles, A.R. Lorimer, P.W. Macfarlane, J.H. McKillop, C.J. Packard, J. Shepherd, and A. Gaw. 2001. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, no. 3:p357.

135. Kulmala, P., K. Savola, H. Reijonen, R. Veijola, P. Vahasalo, J. Karjalainen, E. Tuomilehto-Wolf, J. Ilonen, J. Tuomilehto, H.K. Akerblom, and M. Knip. 2000. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood Diabetes in Finland Study Group. Diabetes 49, no. 1:p48.

136. Kulmala, P., J. Rahko, K. Savola, P. Vahasalo, R. Veijola, M. Sjoroos, A. Reunanen, J. Ilonen, and M. Knip. 2000. Stability of autoantibodies and their relation to genetic and metabolic markers of Type I diabetes in initially unaffected schoolchildren. Diabetologia 43, no. 4:p457.

137. Hathout, E.H., W. Thomas, M. El-Shahawy, F. Nahab, and J.W. Mace. 2001. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 107, no. 6:pE102.

138. Torn, C., M. Landin-Olsson, J. Ostman, B. Schersten, H. Arnqvist, G. Blohme, E. Bjork, J. Bolinder, J. Eriksson, B. Littorin, L. Nystrom, G. Sundkvist, and A. Lernmark. 2000. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16, no. 6:p442.

139. Torn, C., M. Landin-Olsson, A. Lernmark, J.P. Palmer, H.J. Arnqvist, G. Blohme, F. Lithner, B. Littorin, L. Nystrom, B. Schersten, G. Sundkvist, L. Wibell, and J. Ostman. 2000. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85, no. 12:p4619.

140. ACE Consensus Development Conference on Guidelines for Glycemic Control. Endocrine Pract. Suppl. Nov/Dec 2001.

141. Robeerge JN, Brubaker PL. 1993. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-240.

142. Drucker DJ. 2003. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 17:161-171.

143. Farilla L, Bulatto A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, di Mario U, Harlan DM, Perfetti R. 2003. Glucagon like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 1344:5149-5158.

144. Baron A, Poon T, Taylor K, Nielsen L, Boies S, Zhou j, Zhuang D, Varns A, Kim D, Fineman M, Kolterman O. 2003. Exenatide (synthetic exendin-4) showed marked HbA1C decline over 5 months in patients with type 2 diabetes failing oral agents in an open-label study. . Diabetes Suppl. 3-LB.

145. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. 2004. Effects of Exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 27:2628-2635.

146. Kanikkannan N, Singh J, Ramarao P. 1999. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. J Control Release 59:99-105.

147. Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E, Chast F, Peynegre R, Selam JL, Slama G. 2001. Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycemic type 2 diabetic patients with oral failure: a cross over study. Diabet Med 18: 614-618.

148. Still JG. 2002. Development of oral insulin: progress and current status. Diabetes Metab Res Rev 18 (Suppl. 1);S29-S37.

149. Bindra S, Rosenstock J, Cefalu WT. 2002. Inhaled insulin: a novel route for insulin delivery. Expert Opin Investig Drugs 11:687-691.

150. Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, Perera AD, Fishman RS, Shapiro DA, Henry R. 2003. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care. 26:2842-2847.

151. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR. 2004. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 27:2356-2362.

152. Korytkowski M. 2002. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 26 Suppl 3:S18-24.

153. Yki-Jarvinen H. 2001. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24: 758-767.

154. Yki-Jarvinen H. 2002. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab re Rev 18:S77-S81.

155. Weng J, Li Y, Xu W, Chen X, Liao Z, Yao B, Deng W, OuX, Hu G. 2003. The effect of short term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients. Chinese Journal of Diabetes 11:10-15.

156. Zhu F, Ji L, Han X, Zhu Y, Zhang H, Zhou X, Chen J, Cai X, Zhang M. 2003. Induction of long term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Chinese Journal of Diabetes 11:5-9.

157. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. 2004. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients associated with improvement of ß-cell function. Diabetes Care 27:2597-2602.

158. Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K. 1995. Residuel ß-cell function and HLA-A24 in IDDM, markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes. 44:1334-1339.

159. Gonen B, Goldman J, Baldwin D, Goldberg RB, Ryan WG, Blix PM, Schanzlin D, Fritz KJ, Rubenstein AH. 1979. Metabolic control in diabetic patients: effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. Diabetes 28:749-753.

160. Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvert AK, Persson A, Osterman J. 1987. Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin dependent) diabetes mellitus. Diabetologia 30:208-213.

161. Steffes MW, Sibley S, Jackson M, Thomas W. 2003. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 26:832-836.

162. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. 2001. Continous subcutaneous insulin infusion therapy for children and adolescents: an option for routine routine diabetes care. Pediatrics 107:351-356.

163. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. 2002. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 141: 490-495.

164. Conrad SC, McGrath MT, Gitelman SE. 2002. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 140:235-240.

165. Willi SM, Planton J, Egede L, Schwarz S. 2003. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr. 143:796-801.

166. McMahon SK, Airey FL, Marangou DA, McElwee KJ, Carne CL, Clarey AJ, Davis EA, Jones TW. 2005. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet Med. 22:92-96.

167. DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. 2004. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 145:380-384.

168. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. 2005. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 28:15-19.

169. Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. 2004. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics. 114:1601-1605.

170. Maniatis AK, Toig SR, Klingensmith GJ, Fay-Itzkowitz E, Chase HP. 2001. Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parenteral perspectives and predictors of metabolic control. Pediatric Diabetes. 2:51-57.

171. Deiss D, Hartmann R, Hoeffe J, Kordonouri O. 2004. Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy. Pediatric Diabetes 5:117-121.

172: Heptulla RA, Allen HF, Gross TM, Reiter EO. 2003. Contuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy. Pediatric Diabetes 5:10-15.

173. Walter YH, Spratt DI, Garreffa S, McLeod JF. 2000. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. Eur J Clin Pharmacol.56:129-33.

174. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N. 1997. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull. 20:354-359

175. Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz. 2000. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther. 293:444-452.

176. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE. 2001. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 24:983-988.

177. Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. 2002. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care. 25:2147-52.

178. Dimitriadis G, Boutati E, Lambadiari V, Mitrou P, Maratou E, Brunel P, Raptis SA. 2004. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest. 34:490-497.

179. Cefalu WT, Rosenstock J, Bindra S. 2002. Inhaled insulin: a novel route for insulin delivery. Expert Opin Investig Drugs. 11:687-691.

180. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA. 2001. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 357:331-335.

181. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR. 2004. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 27:2356-2362.

182. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. 2004. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab. 17:222-229.

183. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. 2003. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 289:1805-1812.

184. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. 2002. Three-month tolerability of orlistat in adolescents with obesity –related comorbod conditions. Obes Res. 10:642-650.

185. Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S. 2001 Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461.